What low dose semaglutide benefits look like in the early weeks

Step 1: The 0.25 mg phase, settling in, not standing still

The first four weeks on semaglutide can feel anticlimactic. You are on 0.25 mg, a dose that was never meant to drive maximum weight loss on its own. Its job is different: it introduces the GLP-1 receptor agonist mechanism gradually so your digestive system has time to adapt. GLP-1 receptors sit in the gut, the pancreas and the brain; when semaglutide activates them, gastric emptying slows, fullness signals strengthen and the drive to eat between meals softens. At 0.25 mg, those effects are present but gentle.

Many people starting out feel mild nausea after the first injection or two, this is by far the most common early side effect, and it is usually why the low starting dose exists in the first place. Moving more slowly through the early phase means fewer people abandon treatment before it has had a fair chance. If you are curious about what the full semaglutide dose pathway looks like, you can read through how each semaglutide dose is structured and what it is designed to achieve on our site.

Weight change at 0.25 mg is variable. Some people see a modest shift; others see very little. Both are normal. The foundation being built here is tolerance and biological engagement with the mechanism, not a race to the scale.

Step 2: Moving to 0.5 mg and 1.0 mg, when the appetite effects sharpen

After four weeks at 0.25 mg, the prescriber will typically move the dose to 0.5 mg, then to 1.0 mg four weeks after that. This is where most people notice a more pronounced change in how hunger feels day to day. Meals feel satisfying with less food. The background noise of thinking about food (the mid-morning snack urge, the automatic reach for something in the evening) tends to quieten.

These are still intermediate doses. The licensed maintenance target for Wegovy is 2.4 mg weekly, and the newer 7.2 mg pen (approved by the MHRA in April 2026) extends the ceiling further. But arriving at those doses steadily matters. Research supporting the STEP 1 trial, which reported around 15% average body-weight reduction over 68 weeks, used this same gradual titration schedule. Rushing the ladder does not produce better outcomes and typically produces worse tolerability.

It is worth knowing that the 1.0 mg and lower doses are also the territory covered by the low-dose semaglutide section of our site, which goes into more detail on what to expect week by week, and you can also find a closer look at what semaglutide 1 mg involves and how it fits into the titration journey on our site.

Step 3: Reaching 1.7 mg and heading toward maintenance (where the trial numbers are made

By the time a patient reaches 1.7 mg) typically around week 12 of treatment, the benefits of the earlier steps have compounded. Appetite suppression is more consistent. Many people report that their relationship with food feels genuinely different rather than just controlled. This is also where side effects, if they have not already eased, tend to become less intrusive as the body finishes adapting.

The 2.4 mg maintenance dose is the point the STEP 1 trial was powered to assess, and our page on the semaglutide 2 mg dose explains what patients can typically expect once they reach that stage of treatment. That 15% average weight loss figure over 68 weeks (significant enough for NICE to recommend semaglutide in its technology appraisal TA875) was built by spending time at each lower dose first. Skipping early doses or rushing titration is not supported by the evidence and is something a responsible prescriber would push back on.

If cost is part of your thinking at this stage, the UK cost context for Wegovy explains what private pricing typically covers and what to watch for in listings that look unusually low.

What the low-dose phase will not tell you

One thing it helps to know before starting: feeling modest effects at 0.25 mg or 0.5 mg does not mean the medicine is not working or will not work. Semaglutide is not a treatment where the first pen is the best guide to the eventual outcome. If you are finding the early weeks underwhelming, that is a common experience and a good reason to stay in close contact with your prescriber rather than stopping.

Equally, the dose titration schedule is a clinical decision. The question of whether to stay longer at a lower dose, increase sooner, or adjust for a side effect is one for your prescriber and the Patient Information Leaflet, not something to change independently. Our prescribers are available seven days a week for exactly these conversations. If you would like to understand the full Wegovy treatment picture before deciding anything, the Wegovy treatment page is the natural starting point, and our free consultation is open whenever you are ready to talk through your situation with a clinician.